Helicobacter pylori reversing the landscape of neoadjuvant immunotherapy for microsatellite stable gastric cancer: a multicenter cohort study
H. pylori infection has emerged as a favorable factor for neoadjuvant immunotherapy in MSS GC, underscoring the importance of considering H. pylori status in preoperative treatment strategies.
Authors
- Dong Cao
- Bo Young Hong (ORCID: https://orcid.org/0000-0001-9290-6173)
- Bixian Luo (ORCID: https://orcid.org/0000-0002-1286-6181)
- Zelai Wu
- Hongming Liu (ORCID: https://orcid.org/0000-0001-5800-6307)
- Li Wang (ORCID: https://orcid.org/0009-0000-1070-742X)
- Weixun Xie
- Weihua Gong (ORCID: https://orcid.org/0000-0002-0213-7313)
- Yong Liu (ORCID: https://orcid.org/0000-0001-7771-4181)
- Chengyu Hu (ORCID: https://orcid.org/0000-0002-0243-7690)
- Yuxin Zhong
Institutions
- Shaoxing University (CN)
- Second Affiliated Hospital of Zhejiang University (CN)
- Shaoxing People's Hospital (CN)
Publication Details
- Journal
- BMC Medicine
- Published
- 2025-04-23
- DOI
- https://doi.org/10.1186/s12916-025-04047-5
- Citations
- 3
- Primary Topic
- Helicobacter pylori-related gastroenterology studies
- Type
- article
- Field-Weighted Citation Impact
- 6.02